Blood cancer protein may predict patient outcomes

NCT ID NCT04546945

Recruiting now Knowledge-focused Sponsor: Asmaa Hassan mohamed Abdel Mawjoud Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at a protein called CD56 in people with blood cancers like multiple myeloma and leukemia. Researchers want to see how common CD56 is and whether it is linked to how well patients do. The study will include 38 newly diagnosed patients and use a lab test called flow cytometry to measure CD56.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors use CD56 levels to better predict how blood cancers will progress.
What could go wrong: This is a small, early observational study, not a treatment trial. It may not find a clear link between CD56 and patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

Contacts and locations

Locations

Assiut University
COMPLETED

Asyut, Egypt
Assiut university
RECRUITING

Asyut, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.